Display options
Cite
Pope E, Lara-Corrales I, Sibbald C, et al. Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial. JAMA Pediatr. 2021;doi: 10.1001/jamapediatrics.2021.4565.
Pope, E., Lara-Corrales, I., Sibbald, C., Liy-Wong, C., Kanigsberg, N., Drolet, B., & Ma, J. (2021). Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial. JAMA pediatrics, . https://doi.org/10.1001/jamapediatrics.2021.4565
Pope, Elena, et al. "Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial." JAMA pediatrics vol. (2021). doi: https://doi.org/10.1001/jamapediatrics.2021.4565
Pope E, Lara-Corrales I, Sibbald C, Liy-Wong C, Kanigsberg N, Drolet B, Ma J. Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial. JAMA Pediatr. 2021 Nov 08; doi: 10.1001/jamapediatrics.2021.4565. Epub 2021 Nov 08. PMID: 34747977; PMCID: PMC8576629.
Copy Download .nbib Format: NLM
Share it on

JAMA Pediatr. 2021 Nov 08; doi: 10.1001/jamapediatrics.2021.4565. Epub 2021 Nov 08.

Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial.

JAMA pediatrics

Elena Pope, Irene Lara-Corrales, Cathryn Sibbald, Carmen Liy-Wong, Nordau Kanigsberg, Beth Drolet, Jin Ma

Affiliations

  1. Division of Pediatric Dermatology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
  2. Division of Dermatology and Rheumatology, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada.
  3. Department of Dermatology, University of Wisconsin-Madison.
  4. Biostatistics Research Unit, University Health Network, Toronto, Ontario, Canada.

PMID: 34747977 PMCID: PMC8576629 DOI: 10.1001/jamapediatrics.2021.4565

Abstract

IMPORTANCE: Propranolol for infantile hemangiomas (IH) has been shown to be effective and relatively safe. However, other less lipophilic β-blockers, such as nadolol, may be preferable in individuals who experience propranolol unresponsiveness or adverse events.

OBJECTIVE: To document the noninferiority and safety of oral nadolol compared with oral propranolol in infants with IH.

DESIGN, SETTING, AND PARTICIPANTS: This double-blind noninferiority prospective study with a noninferiority margin of 10% compared propranolol with nadolol in infants aged 1 to 6 months with problematic IH. The study was conducted in 2 academic pediatric dermatology centers in Canada between 2016 and 2020. Infants aged 1 to 6 months with a hemangioma greater than 1.5 cm on the face or 3 cm or greater on another body part causing or with potential to cause functional impairment or cosmetic disfigurement.

INTERVENTIONS: Oral propranolol and nadolol in escalating doses up to 2 mg/kg/d.

MAIN OUTCOMES AND MEASURE: Between-group differences comparing changes in the bulk (size and extent) and color of the IH at week 24 with baseline using a 100-mm visual analog scale.

RESULTS: The study included 71 patients. Of these, 36 were treated with propranolol. The mean (SD) age in this group was 3.1 (1.4) months, and 31 individuals (86%) were female. Thirty-five infants were treated with nadolol. The mean (SD) age in this group was 3.2 (1.6) months, and 26 individuals (74%) were female. The difference in IH between groups by t test was 8.8 (95% CI, 2.7-14.9) for size and 17.1 (95% CI, 7.2-30.0) for color in favor of the nadolol group, demonstrating that nadolol was noninferior to propranolol. Similar differences were noted at 52 weeks: 6.0 (95% CI, 1.9-10.1) and 10.1 (95% CI, 2.9-17.4) for size and color improvement, respectively. For each doubling of time unit (week), the coefficient of involution was 2.4 (95% CI, 0.5-4.4) higher with nadolol compared with propranolol. Safety data were similar between the 2 interventions.

CONCLUSIONS AND RELEVANCE: Oral nadolol was noninferior to oral propranolol, indicating it may be an efficacious and safe alternative in cases of propranolol unresponsiveness or adverse events, or when faster involution is required.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02505971.

References

  1. Arch Dermatol. 2012 Feb;148(2):197-202 - PubMed
  2. Br J Dermatol. 2013 Jan;168(1):222-4 - PubMed
  3. N Engl J Med. 2015 Feb 19;372(8):735-46 - PubMed
  4. Biomed Res Int. 2019 Nov 25;2019:2728952 - PubMed
  5. N Engl J Med. 2008 Jun 12;358(24):2649-51 - PubMed
  6. Br J Dermatol. 2015 Jan;172(1):13-23 - PubMed
  7. Drugs. 1980 Jul;20(1):1-23 - PubMed
  8. Pediatr Dermatol. 2015 Sep-Oct;32(5):690-5 - PubMed
  9. Pediatrics. 2016 Oct;138(4): - PubMed
  10. J Am Coll Cardiol. 1992 Mar 1;19(3):630-5 - PubMed
  11. Pediatrics. 2011 Aug;128(2):e259-66 - PubMed
  12. Pediatrics. 2018 Sep;142(3): - PubMed
  13. J Am Acad Dermatol. 2015 Aug;73(2):258-63 - PubMed
  14. J Clin Pharmacol. 1977 May-Jun;17(5-6):300-7 - PubMed
  15. Br J Dermatol. 2014 Apr;170(4):907-13 - PubMed
  16. Pediatr Dermatol. 2015 Nov-Dec;32(6):853-7 - PubMed
  17. J Am Acad Child Adolesc Psychiatry. 1997 Jun;36(6):826-34 - PubMed
  18. Br J Dermatol. 2016 Mar;174(3):594-601 - PubMed
  19. Pediatrics. 2013 Jan;131(1):128-40 - PubMed
  20. Arch Dermatol. 2000 Jul;136(7):905-14 - PubMed
  21. Pharmacol Ther. 1990;46(2):163-97 - PubMed
  22. Pediatr Dermatol. 2005 Sep-Oct;22(5):383-406 - PubMed
  23. Pharmacol Res Perspect. 2019 Jul 12;7(4):e00496 - PubMed
  24. Pediatr Dermatol. 2021 Mar;38(2):371-377 - PubMed

Publication Types